{"id":"arac","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"60-70","effect":"Nausea and vomiting"},{"rate":"40-50","effect":"Mucositis"},{"rate":"10-20","effect":"Hepatotoxicity"},{"rate":"5-15","effect":"Neurotoxicity (at high doses)"},{"rate":"30-40","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3350507","moleculeType":"Small molecule","molecularWeight":"766.96"},"_dailymed":{"setId":"97e5c6c0-7101-49b7-8ac4-9dfc60f60cc5","title":"ANIMAL ALLERGENS, AP CATTLE HAIR AND DANDER (CATTLE HAIR AND DANDER) INJECTION, SOLUTION ANIMAL ALLERGENS, AP DOG HAIR AND DANDER CANIS SPP (ANIMAL ALLERGENS, DOG DANDER CANIS SPP) INJECTION, SOLUTION ANIMAL ALLERGENS, DOG HAIR AND DANDER CANIS SPP. (DOG HAIR CANIS SPP.) INJECTION, SOLUTION ANIMAL ALLERGENS, AP HORSE HAIR AND DANDER (AP HORSE HAIR .......CTION, SOLUTION POLLENS - TREES, MULBERRY MIX (MULBERRY MIX) INJECTION, SOLUTION POLLENS - TREES, OAK MIX (OAK MIX) INJECTION, SOLUTION POLLENS - TREES, OAK, RED QUERCUS RUBRA (OAK, RED QUERCUS RUBRA) INJECTION, SOLUTION ANIMAL ALLERGENS, UF DOG HAIR-DANDER CANIS SPP (ANIMAL ALLERGENS, DOG DANDER CANIS SPP) INJECTION, SOLUTION [JUBILANT HOLLISTERSTIER LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AraC is converted intracellularly to its active triphosphate form, which competes with deoxycytidine triphosphate for incorporation into DNA. Once incorporated, it causes chain termination and prevents further DNA replication, leading to cell death. It is primarily effective against rapidly dividing cells, particularly hematopoietic malignancies.","oneSentence":"AraC (cytarabine) is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:12.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Chronic myeloid leukemia (CML) in blast crisis"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT02286726","phase":"PHASE2","title":"CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT07425782","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine for Consolidation Therapy in AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax","enrollment":216},{"nctId":"NCT03896269","phase":"PHASE1","title":"CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-14","conditions":"Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia","enrollment":38},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT03629171","phase":"PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-29","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT03672539","phase":"PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-11-07","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT04915612","phase":"PHASE1","title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-21","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT04269213","phase":"PHASE2","title":"CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2021-07-29","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia","enrollment":21},{"nctId":"NCT04802161","phase":"PHASE2","title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia","enrollment":50},{"nctId":"NCT04128748","phase":"PHASE1, PHASE2","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-27","conditions":"Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT04493164","phase":"PHASE2","title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-30","conditions":"Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm","enrollment":30},{"nctId":"NCT02115295","phase":"PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-05-19","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":508},{"nctId":"NCT03125642","phase":"PHASE2","title":"Auto Stem Cell Transplant for Lymphoma Patients","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04-20","conditions":"Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT02756962","phase":"PHASE2","title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2016-07-06","conditions":"Acute Myeloid Leukemia","enrollment":107},{"nctId":"NCT07187193","phase":"PHASE2","title":"Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-12","conditions":"Langerhans Cell Histiocytosis","enrollment":50},{"nctId":"NCT03878199","phase":"PHASE1, PHASE2","title":"Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2019-02-20","conditions":"Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm","enrollment":12},{"nctId":"NCT04385290","phase":"PHASE1, PHASE2","title":"Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2020-09-04","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT00878254","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-03-25","conditions":"Mantle-Cell Lymphoma","enrollment":25},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT04049539","phase":"PHASE1, PHASE2","title":"Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2021-01-29","conditions":"Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT01865110","phase":"PHASE3","title":"R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-11","conditions":"Mantle Cell Lymphoma","enrollment":623},{"nctId":"NCT06830421","phase":"PHASE3","title":"Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients","status":"RECRUITING","sponsor":"University Hospital Freiburg","startDate":"2023-08-09","conditions":"Primary Central Nervous System Lymphoma","enrollment":340},{"nctId":"NCT04526288","phase":"PHASE2","title":"CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-08-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm","enrollment":1},{"nctId":"NCT01497002","phase":"PHASE3","title":"Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2005-04","conditions":"Acute Myeloid Leukaemia","enrollment":1222},{"nctId":"NCT03904251","phase":"PHASE1","title":"CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-07-18","conditions":"Acute Myelogenous Leukemia","enrollment":13},{"nctId":"NCT03825796","phase":"PHASE2","title":"CPX-351 Plus Enasidenib for Relapsed AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-12","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT02642965","phase":"PHASE1, PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2016-05-02","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","enrollment":38},{"nctId":"NCT05320380","phase":"PHASE1, PHASE2","title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2023-08-01","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia","enrollment":""},{"nctId":"NCT00744081","phase":"PHASE2","title":"Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2004-07","conditions":"AML","enrollment":130},{"nctId":"NCT02686593","phase":"PHASE2","title":"Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-02-01","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05528354","phase":"EARLY_PHASE1","title":"Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-06-02","conditions":"Hematopoietic Stem Cell Transplantation, TP53","enrollment":58},{"nctId":"NCT01516593","phase":"PHASE2","title":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"HIV, Burkitt's Lymphoma","enrollment":19},{"nctId":"NCT04326439","phase":"PHASE2","title":"AflacLL1901 (CHOA-AML)","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-24","conditions":"Acute Myeloid Leukemia, AML, Childhood","enrollment":8},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT03563560","phase":"PHASE1","title":"A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2018-05-15","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT01158885","phase":"PHASE2","title":"Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08","conditions":"Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute","enrollment":2},{"nctId":"NCT00703820","phase":"PHASE3","title":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-08-04","conditions":"Acute Myeloid Leukemia","enrollment":324},{"nctId":"NCT01861002","phase":"PHASE1","title":"A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2013-05-22","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood","enrollment":15},{"nctId":"NCT04121819","phase":"PHASE2","title":"AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-10-01","conditions":"Langerhans Cell Histiocytosis","enrollment":40},{"nctId":"NCT03718143","phase":"PHASE2","title":"AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2019-05-08","conditions":"Myelofibroses, Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT00939653","phase":"PHASE2","title":"T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-07-10","conditions":"Relapsed Acute Myelogenous Leukemia","enrollment":6},{"nctId":"NCT04178343","phase":"NA","title":"Tomotherapy for Leptomeningeal Metastases","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-09-01","conditions":"Leptomeningeal Metastasis","enrollment":103},{"nctId":"NCT02611492","phase":"PHASE3","title":"A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04","conditions":"Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia","enrollment":265},{"nctId":"NCT02535806","phase":"PHASE2","title":"Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults","status":"TERMINATED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2015-07","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":2},{"nctId":"NCT02717884","phase":"PHASE1, PHASE2","title":"Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)","status":"UNKNOWN","sponsor":"Michael Luebbert","startDate":"2015-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":60},{"nctId":"NCT02351037","phase":"PHASE2","title":"Study of Ibrutinib in Subjects With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Pharmacyclics LLC.","startDate":"2015-02","conditions":"Acute Myeloid Leukemia (AML)","enrollment":36},{"nctId":"NCT02101983","phase":"NA","title":"Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2011-05","conditions":"Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT03564704","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT03553238","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic","enrollment":70},{"nctId":"NCT01804101","phase":"NA","title":"Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-05-07","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":48},{"nctId":"NCT00055874","phase":"PHASE3","title":"Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2002-06","conditions":"Leukemia","enrollment":1551},{"nctId":"NCT02280993","phase":"PHASE1","title":"Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients","status":"UNKNOWN","sponsor":"Marjolein Spiering","startDate":"2014-05","conditions":"Hodgkin Lymphoma, Refractory, Relapse","enrollment":72},{"nctId":"NCT00945815","phase":"PHASE2","title":"S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2010-09","conditions":"Leukemia","enrollment":35},{"nctId":"NCT01457040","phase":"PHASE2, PHASE3","title":"Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2011-10","conditions":"Acute Lymphoblastic Leukemia, Stem Cell Transplantation, Hematopoietic","enrollment":200},{"nctId":"NCT03045627","phase":"PHASE2","title":"Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2017-01","conditions":"Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT02845232","phase":"","title":"Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-03","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT00646750","phase":"PHASE2","title":"Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2008-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":31},{"nctId":"NCT00450801","phase":"PHASE2","title":"R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-04","conditions":"Lymphoma","enrollment":22},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01502982","phase":"PHASE2","title":"Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)","status":"COMPLETED","sponsor":"Nordic Lymphoma Group","startDate":"2004-11","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":160},{"nctId":"NCT00004056","phase":"PHASE1","title":"Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-10","conditions":"Leukemia","enrollment":35},{"nctId":"NCT02182596","phase":"PHASE1, PHASE2","title":"DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML","status":"COMPLETED","sponsor":"Acute Leukemia French Association","startDate":"2006-06","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT01139151","phase":"PHASE1","title":"4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08","conditions":"Leukemia","enrollment":31},{"nctId":"NCT02024308","phase":"PHASE4","title":"AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2010-11","conditions":"Acute Myeloid Leukemia, AML1-ETO Fusion Protein Expression","enrollment":62},{"nctId":"NCT00112554","phase":"PHASE3","title":"Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Vion Pharmaceuticals","startDate":"2005-03","conditions":"Leukemia","enrollment":420},{"nctId":"NCT00070187","phase":"PHASE2, PHASE3","title":"Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-11","conditions":"Lymphoma","enrollment":24},{"nctId":"NCT00927498","phase":"PHASE3","title":"A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old","status":"COMPLETED","sponsor":"Acute Leukemia French Association","startDate":"2007-12","conditions":"Acute Myeloid Leukemia","enrollment":280},{"nctId":"NCT00003593","phase":"PHASE3","title":"Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-06","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":254},{"nctId":"NCT01230983","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-06","conditions":"Cardiac Toxicity, Leukemia, Lymphoma","enrollment":573},{"nctId":"NCT00915252","phase":"PHASE2","title":"Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2009-07","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT00366275","phase":"PHASE2","title":"Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2002-01","conditions":"Follicular Lymphoma","enrollment":64},{"nctId":"NCT00266136","phase":"PHASE3","title":"Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"1999-06","conditions":"Acute Myeloid Leukemia","enrollment":3500},{"nctId":"NCT00838240","phase":"PHASE1, PHASE2","title":"Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2008-11","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":114},{"nctId":"NCT01414231","phase":"PHASE3","title":"Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a","status":"UNKNOWN","sponsor":"University of Leipzig","startDate":"2002-04","conditions":"Acute Myeloid Leukaemia","enrollment":850},{"nctId":"NCT00180167","phase":"PHASE4","title":"Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2005-01","conditions":"Leukemia, Nonlymphocytic, Acute","enrollment":492},{"nctId":"NCT00880243","phase":"PHASE3","title":"Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Acute Leukemia French Association","startDate":"1999-03","conditions":"Acute Myeloid Leukemia","enrollment":473},{"nctId":"NCT00599937","phase":"PHASE3","title":"APL93: Timing of CxT and Role of Maintenance","status":"COMPLETED","sponsor":"Groupe d'etude et de travail sur les leucemies aigues promyelocytaires","startDate":"1993-01","conditions":"Leukemia, Promyelocytic, Acute","enrollment":576},{"nctId":"NCT00591526","phase":"PHASE3","title":"A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)","status":"COMPLETED","sponsor":"Groupe d'etude et de travail sur les leucemies aigues promyelocytaires","startDate":"2000-06","conditions":"Leukemia, Promyelocytic, Acute","enrollment":250},{"nctId":"NCT00199186","phase":"PHASE2","title":"Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)","status":"UNKNOWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2002-03","conditions":"Philadelphia Positive Acute Lymphoblastic Leukemia, Lymphoid Blastic Phase of Chronic Myeloid Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"FUNGAL INFECTION"},{"count":4,"reaction":"PNEUMONIA"},{"count":3,"reaction":"ACUTE LYMPHOCYTIC LEUKAEMIA"},{"count":3,"reaction":"GASTROINTESTINAL NECROSIS"},{"count":3,"reaction":"MULTI-ORGAN FAILURE"},{"count":3,"reaction":"PYREXIA"},{"count":2,"reaction":"ABDOMINAL DISTENSION"},{"count":2,"reaction":"ACIDOSIS"},{"count":2,"reaction":"ACUTE GRAFT VERSUS HOST DISEASE"}],"_approvalHistory":[],"publicationCount":6424,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cytarabine","Ara-C","Arabinosylcytosine","Cytosar-U","cytosine arabinoside"],"phase":"marketed","status":"active","brandName":"AraC","genericName":"AraC","companyName":"University of California, San Diego","companyId":"university-of-california-san-diego","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AraC (cytarabine) is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast crisis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}